Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse
Clinical trial NCT06910124 · RECRUITING
Trial details
- NCT number
- NCT06910124
- Sponsor
- Dickran Kazandjian, MD
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-12-02
- Primary completion
- 2032-12-02
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.